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Abstract
Background: Salmeterol and fluticasone combination (SFC) has anti-inflammatory effects and improves clinical
symptoms in patients with chronic obstructive pulmonary disease (COPD). However, the anti-inflammatory
mechanism of SFC remains unclear. In this study, we investigated the inflammatory responses of COPD, as well as
the relationship of the inflammatory factors with the levels of CD4
+CD25
+Foxp3
+ regulatory T cells (Foxp3
+Tregs)
after SFC therapy.
Methods: Twenty-one patients with moderate or severe COPD received treatment with 50/500 μg of SFC twice a
day for 12 weeks. Before and after treatment, the patients were evaluated using the Modified Medical Research
Council (MMRC) dyspnea scale and by conducting a 6-min walk test. The number of neutrophils, monocytes and
lymphocytes in induced sputum were counted. Levels of cytokines, including pre-inflammatory IL-8, TNF-a, IL-17A
and cytokine IL-10, in the sputum supernatant and peripheral blood were measured by ELISA. The proportion of
Foxp3
+Tregs in the total CD4
+ T cell of the peripheral blood was determined by flow cytometry. The relationship
between IL-17A levels and the percentage of Foxp3
+Tregs was analyzed by statistical analysis.
Results: After treatment with SFC, the forced expiratory volume in 1 s as a percentage of predicted values (FEV1%)
and the 6-min walk distance in the COPD patients significantly increased, while dyspnea scores decreased. The
total number of cells, neutrophils, and the percentage of neutrophils in induced sputum reduced notably, while
the proportion of monocytes was significantly increased. Levels of the inflammatory cytokines IL-8, TNF-a, and IL-
17A in the sputum supernatant and in the blood were markedly lowered, while IL-10 levels were unchanged. The
proportion of Foxp3
+Tregs in the total CD4
+T cell population in the peripheral blood was drastically higher than
that before treatment. The level of IL-17A was negatively correlated with the proportion of Foxp3
+Tregs in CD4
+T
cells.
Conclusion: SFC can reduce the levels of inflammatory factors and improve symptoms of COPD. The levels of
inflammatory factors are associated with the variation of Foxp3
+Tregs in COPD.
Trial registration: This study was registered with http://www.chictr.org (Chinese Clinical Trial Register) as follows:
ChiCTR-TNC-10001270
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Chronic obstructive pulmonary disease (COPD) is a
chronic disorder characterized by persistent inflamma-
tion of the lung [1,2], which is mainly caused by cigar-
ette smoking and inhalation of polluted gas or particles.
Tobacco smoking is considered the primary risk factor
for COPD [3]. Although the pathophysiological progres-
sion of COPD can be delayed by quitting smoking, the
inflammatory reactions will continue and is irreversible
[4-6].
Recent reports indicate that the acquired immune
response is involved in the pathogenesis of COPD [7].
This could account for the persistence of inflammation
in the lungs after COPD patients stop smoking. First,
epithelial cells damaged by smoking release chemokines
and cytokines to activate and stimulate chemotaxis of
neutrophils and alveolar macrophages, which initiate
innate inflammation. This process also leads to matura-
tion and migration of dendritic cells into pulmonary
lymphoid tissues, the secretion of inflammatory cyto-
kines, and CD4
+/CD8
+ T cell differentiation and migra-
tion into the lung. Immune regulation and immune
tolerance determine the immune response to and out-
come of COPD. If the dendritic cells lose immune toler-
ance to autoantigens from inflammation-injured lung
tissue, they will activate type 1 helper T cells (Th1) and
cytotoxic CD8
+ T cells, and trigger the acquired
immune response and inflammation [4]. CD4
+CD25
+Foxp3
+ regulatory T cells (Foxp3
+Tregs) play an
important role in the regulation of these processes [8].
Reduction in the number of Tregs weakens immune tol-
erance to autoantigens [9]. The number of Tregs in the
lungs of smokers without lung dysfunction is more than
that in people without a history of smoking [4]. Tregs
may be involved in the maintenance of normal lung
function in smokers and may stop the progression of
immune responses [10]. Furthermore, Foxp3
+Tregs
could improve prognoses in cases of acute exacerbation
of COPD [11].
Acquired immune response-related cytokines and
inflammatory mediators actively participate in the
pathogenesis of COPD. A better understanding of the
acquired immune response and T cells will lead to
improved intervention strategies in cases of COPD and
will help reduce airway inflammation. A variety of treat-
ments can relieve the symptoms and improve the quality
of life of COPD patients, but these treatments cannot
control inflammation or block the progression of COPD
[12]. Inhaled long-acting bronchodilators alleviate symp-
toms to some extent and improve patients’ lung func-
tion and quality of life. Corticosteroids inhalation can
avoid acute exacerbation of patients’ symptoms and
reduce frequent deterioration of a patient’sc o n d i t i o n .A
combination of bronchodilators, salmeterol, and a
corticosteroid, or fluticasone propionate (SFC) has better
efficacy than either drug has [13-15]. SFC has been
shown to have anti-inflammatory effects in patients with
COPD [16], which contributed to an improvement in
symptoms. However, whether the clinical efficacy of
SFC is mediated by Foxp3
+Tregs in peripheral blood is
unknown. In this study, we hypothesized that SFC alle-
viated inflammation in patients with COPD by increas-
ing the percentage of Foxp3
+Tregs in the peripheral
blood to enhance immune tolerance, thereby reducing
the total numbers of cells and neutrophils in induced
sputum, and reducing the levels of inflammatory factors
such as IL-8, TNF-a, and IL-17A.
Methods
Subjects
A total of 21 subjects with a clinical diagnosis of stable
COPD [1] at or above mid range were enrolled between
September 2009 and January 2010 from outpatient
clinics at the Xinqiao Hospital, Chongqing, China. The
eligibility criteria for the study were as follows: age
between 40 and 79 years, habit of smoking or a history
of smoking (≥ 10 pack-years), forced expiratory volume
in 1 s (FEV1) after administration of a bronchodilator <
80% of the predicted value, FEV1/forced vital capacity
(FVC) < 70% of the predicted value, and no history of
asthma, atopy (as defined by a positive reaction to one
or more allergen in a fluoro- enzyme immunoassay) or
any other active lung disease. Subjects were either newly
diagnosed or had not received corticosteroids (either
oral or inhaled), antibiotics, or any other long-acting b2-
agonists for a minimum of 30 days prior to the com-
mencement of the study. All subjects had been free
from respiratory tract infections or COPD exacerbation
for 12 weeks prior to the pulmonary function tests and
sputum induction. Eleven subjects with a smoking his-
tory (≥ 10 pack-years) and normal lung function were
used as healthy control. The study protocol was
approved by the ethics review board of the Second
Affiliated Hospital, Third Military Medical University,
China. Written informed consent was obtained from all
participants, and all of the procedures were done in
accordance with the Declaration of Helsinki and rele-
vant policies in China. The protocol was also proved by
Chinese Clinical Trial Register (Chengdu, China). Trial
registration number: ChiCTR-TNC-10001270.
Study design
The study was an own anterior-posterior control clinical
trial, with the subjects allocated to receive treatment as
follows: SFC 50/500 μg per puff, 2 puffs twice daily by
using an Evohaler (GlaxoSmithKline, Ware, UK). Use of
theophylline and any other short-acting b2-agonists was
discontinued during the study. The treatment duration
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12. Peripheral blood was collected from healthy control
and test subjects. The percentage of Foxp3
+ Tregs as a
proportion of the total CD4
+T cells in the blood was
tested by flow cytometry. The peripheral blood samples
were stored at -70°C, and the levels of IL-8, TNF-a,I L -
10, and IL-17A in the blood were subsequently tested
using ELISA (R&D Systems, Abingdon, UK) according to
the manufacturer’s instructions. Induced sputum was
processed as described previously [17,18], and the super-
natant was aspirated and frozen at -70°C prior to the
measurement of inflammatory mediators. The levels of
inflammatory mediators, including IL-8, TNF-a,I L - 1 0 ,
and IL-17A, in the supernatants were assayed using
ELISA. Pulmonary function tests, sputum induction, the
6-min walk distance [19], and assessment of health-
related quality of life were carried out in the morning at
screening and in week 0 and 12. Health status was
assessed using the MMRC scale (Figure 1).
Peripheral blood collection and processing
The peripheral blood samples were collected in heparin-
treated tubes from each subject in week 0 and 12. Eight
milliliters of peripheral blood were drawn simulta-
neously. Four milliliters of peripheral blood was isolated
for lymphocytes. Surplus were centrifuged at 1,200 g for
10 min. The cell-free supernatants of serum were frozen
at -70°C for determining cytokine concentrations.
Flow cytometry and FACS analysis
The expression markers on T cells from blood were
determined by flow cytometry after surface staining or
intracellular staining with anti-CD4, anti-CD25, and
anti-Foxp3 mAbs Human Regulatory T cell Staining Kit
(eBioscience, Inc, San Diego, USA). Peripheral blood
mononuclear cells (PBMCs)w e r ei s o l a t e df r o mw h o l e
blood on a discontinuous Histopaque density gradient
(Sigma). The extracellular cells were stained with fluor-
escein isothiocyanate (FITC) conjugated anti-human
CD4, allophycocyanin (APC) conjugated anti-human
CD25 (eBioscience, Inc, San Diego, USA). Lymphocytes
were gated in FSC and SSC stained. The percentage of
CD4
+ cell type was counted out of gated CD4
+ cells in
lymphocytes. CD25
+ cells were expressed on the gated
CD4 cells. Intracellular staining of phycoerytrin (PE)
conjugated anti-human Foxp3 was conducted according
to the recommended procedure (eBioscience, Inc, San
Diego, USA). Each sample was added freshly eBioscience
Foxp3 fixation/permeablization buffer and incubated at
4°C for 60 minutes. cells were washed and centrifuged
at 4°C for 10 minutes, 300 g. Anti-human Foxp3 antibo-
d i e sw e r eu s e di nt h es a m et e s tt u b e .T h ep e r c e n t a g e
Foxp3
+ was determined out of gated CD4
+ lymphocytes.
Flow cytometry data acquisition was performed on a
FACS Calibur equipped with 488 and 633 nm lasers and
running Cellquest Software (Becton Dickinson, CA,
USA). Fifty thousand live-gated events were collected
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Figure 1 Schematic diagram for study design.
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used to determine binding specificity. Flowjo software
was used for data analysis (Treestar, OR, USA).
Sputum induction and processing
Sputum was induced as reported by Pin et al. [17]. In
short, a 3% hypertonic saline solution was nebulized via
anultrasonic nebulizer and inhaled by the subjects. The
sputum collected from each subject was pooled and
kept at 4°C for not more than 2 hours prior to further
processing. The sputum was stained with Giemsa stain
and then processed with dithiothreitol at a final concen-
tration of 0.1%, as has been described. Sputum was
diluted and centrifuged (1,500 g, 4°C, 10 min) and then
the supernatants were stored at -70°C for determining
cytokine concentrations. Differential cell counts were
expressed as the percentage of non-squamous cells [18].
Absolute cell numbers were calculated as (% cell × total
cell count)/(sputum weight). The percentage of squa-
mous cell < 20% were qualified.
Enzyme-linked immunosorbent assay (ELISA)
The concentrations of IL-8, TNF-a, IL-10, and IL-17A
in the supernatant of the peripheral blood and induced
sputum were measured by sandwich ELISA kits accord-
ing to the manufacturer’s protocols (R&D Systems,
Abingdon, UK). The lower detection limits of IL-8,
TNF-a, IL-10, and IL-17A were 62 pg/ml, 20 pg/ml,
12.5 pg/ml, and 62.5 pg/ml, respectively.
Pulmonary function test
Dynamic spirometry (FVC and FEV1) was performed
pre- and post- bronchodilatation using a Vitalograph
Spirometer (Jaeger, Würzburg, Germany) according to
the guidelines of the American Thoracic Society.
Six-min walk distance and MMRC scale
COPD patients were requested to walk a 30-m course in
a flat corridor back and forth for 6 minutes (6-min walk
test). Patients may rest if they were too short of breath
to continue after adequate encouragement.
The degree of dyspnea was measured with the use of
the modified Medical Research Council (MMRC) dys-
pnea scale. The scores range from 0 to 4, with a score
of 4 indicating that the patient is breathless when dres-
sing or undressing [19].
Statistical analysis
Statistical analysis was performed using the SPSS 15.0
statistical package. Data are expressed as mean ± SEM.
For multiple comparisons, statistical analysis was per-
formed using ANOVA, and the post hoc test was subse-
quently applied as the least significant difference test for
pairwise comparisons. Association in treatment
differences (pre-treatment minus post-treatment)
between the levels of IL-17A and the proportion of
Foxp3Tregs, as a percentage of total CD4
+T cells, was
measured using Spearman’s rank correlation test. A p
value of 0.05 was considered significant for all tests.
Results
Subject characteristics
All of the 21 patients with COPD (20 men and 1 woman,
aged 40-79 years, mean 66 years) had a history of smoking.
Eight patients had moderate COPD, and 13 had severe
COPD. The smoking index ranged from 12.5 to 89 packs
per year, with an average of 36 packs per year. The FEV1
percentage after treatment (post-FEV1%) was 27% to 65%
(mean 45.62 ± 12.06%). The mean FEV1 value was 1.16 ±
0.38 L (Table 1). None of the patients experienced exacer-
bation of symptoms during the study period.
Effect of SFC therapy on lung function and quality of life
in COPD patients
In the cases of patients treated with SFC for 12 weeks
without bronchodilators, FEV1% values increased signifi-
cantly (p = 0.016) from 39.62 ± 2.35% (before therapy) to
46.10 ± 3.58% (pre-FEV1%). Administration of bronchodi-
lators further increased FEV1% to 49.00 ± 3.22% (post-
FEV1%), but this change did not reach statistical signifi-
cance (p = 0.100) relative to the values before treatment
(45.62 ± 2.63%). The pre-FEV1 values and post-FEV1
values also showed no significant difference before (1.02 ±
0.07 L and 1.16 ± 0.08 L, respectively) and after SFC ther-
apy (1.15 ± 0.13 L and 1.27 ± 0.11 L, respectively). The
value of mean reversibility significantly decreased (p =
0.048) from 0.15 ± 0.03 L to 0.08 ± 0.02 L, but the
Table 1 Characteristics of COPD patients and health
COPD Health
Subjects (n) 21 11
Males (n) 20 9
Females (n) 1 2
Mean age (years) 66.19 ± 8.43 63.55 ± 6.58
Duration of disease (years) 12.95 ± 9.17 -
Smoking history (pack-years) 36.45 ± 20.18 -
Mean FEV1(L) 1.16 ± 0.38 2.45 ± 0.69
Mean FEV1%, predicted 45.62 ± 12.06 103.82 ± 17.05
Post-FEV1%, > 80% (n) 0 11
Post-FEV1% 50%-80% (n) 8 0
Post-FEV1% 30%-50% (n) 13 0
Mean FVC (L) 3.19 ± 0.86 3.21 ± 0.83
Mean FEV1/FVC(%) 36.76 ± 9.27 76.18 ± 4.47
Mean reversibility (%) 14.05 ± 13.33 -
Mean reversibility (L) 0.15 ± 0.13 -
Data are presented as mean ± SD.
FEV1, forced expiratory volume in 1 s. FVC, forced vital capacity.
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before therapy vs. 8.19 ± 1.96% after therapy) was not sig-
nificant. Regarding clinical parameters, after the combina-
tion therapy, dyspnea measurements were significantly
lower (2.24 ± 0.01 before vs. 1.33 ± 0.11 after treatment)
(p < 0.001), and the 6-minute walk distance was signifi-
cantly greater (329.52 ± 8.82 m before vs. 367.14 ± 7.99 m
after therapy) (p < 0.001) (Table 2). These data show that
the quality of life of the COPD subjects improved after
SFC therapy.
Effect of SFC therapy on the induced sputum of
moderate and severe COPD patients
After SFC therapy for 12 weeks, the total number of
cells and neutrophils in the induced sputum significantly
d e c r e a s e df r o m3 . 1 3×1 0
6 cells/g to 2.09 × 10
6 cells/g
(p = 0.002), and from 2.29 × 10
6 cells/g to 1.24 × 10
6
cells/g (p < 0.001) as compared with baseline (Figure 2).
While monocyte numbers in the induced sputum kept
little change (from 0.74 × 10
6 cells/g to 0.78 × 10
6 cells/
g, p = 0.76, Figure 2). The similar with these tendencies,
the percentage of neutrophils and monocytes decreased
by 14.26% (p = 0.001) and 13.81% (p = 0.001) as com-
pared with baseline, respectively. Indeed, differences in
the absolute number and percentages of lymphocytes
and eosinophils before and after SFC treatment were
not significant, respectively (p > 0.05, Figure 2). These
results suggest that the number of total and neutrophils
reduce and neutrophil-related inflammation in the air-
ways is ameliorated after SFC therapy.
The distinction between moderate and severe COPD
patients in the induced sputum was compared with each
other in statistical methods. The results showed that, for
severe COPD patients, total cell numbers and neutrophil
numbers marked decreased from 3.15 ± 0.44 to 2.05 ±
0.27 (× 10
6/g), 2.35 ± 0.31 to 1.25 ± 0.18 (× 10
6/g) after
SFC therapy (p = 0.02, p = 0.001, Additional file 1Table
S1). For moderate COPD patients, neutrophil numbers
much reduced from 2.19 ± 0.34 to 1.23 ± 0.24 (× 10
6/g)
after SFC treatment (p = 0.02, Additional file 1Table S1).
T h e r ea r en od i f f e r e n c ea b o u tt h em o n o c y t en u m b e r si n
moderate and severe COPD between before and after
SFC therapy (p = 0.90, p = 0.75). And there are no differ-
ence about total cell numbers and the percentage of neu-
trophils and monocytes in moderate COPD patients after
SFC therapy (p = 0.08, p = 0.10, p = 0.12). There are no
difference about the lymphocytes and eosinophils in the
induced sputum, neither in moderate nor severe COPD
(Additional file 1Table S1). These data suggest that there
is an obviously change about inflammatory cells in total
and severe COPD patients at present subjects.
Effect of SFC therapy on the levels of inflammatory
mediators in induced sputum and serum
Levels of the inflammatory factors IL-8, TNF-a, and IL-
17A in the supernatant of induced sputum decreased
significantly to 25.69 ± 3.50 ng/ml (p < 0.001), 562.79 ±
29.76 pg/ml (p < 0.001), and 0.33 ± 0.03 ng/ml (p =
0.025), respectively, after SFC therapy (Table 3). The
increase in IL-10 level in the sputum after treatment
was not statistically significant (p = 0.121). After treat-
m e n t ,t h el e v e l so fI L - 8 ,T N F - a, and IL-17A in serum
also decreased significantly to 7.53 ± 0.40 ng/ml, 148.97
± 14.33 pg/ml, and 0.95 ± 0.06 ng/ml, respectively (p <
0.001, p = 0.008, p = 0.022, respectively, Table 4). The
increase in the serum levels of IL-10 was not significant
(p = 0.785, Tables 3 and 4). These data showed that the
levels of inflammatory factors in COPD subjects
decreased after SFC therapy.
Effect of SFC therapy on the expression of CD4
+CD25
+Foxp3
+ Treg cells
Since Foxp3
+Tregs have been shown to participate in
immunoregulatory mechanisms, we investigated whether
the percentage of Foxp3
+Tregs in CD4
+ T cells is altered
after treatment. The results are shown in Figure 3.
After the 12-week SFC therapy, the proportion of
Foxp3
+T r e g sa sap e r c e n t a g eo ft o t a lC D 4
+ T cells in
the peripheral blood of COPD patients significantly
increased from 3.33 ± 0.23% to 4.14 ± 0.21% (p <
0.001), as analyzed by flow cytometry. However, the per-
centage of Foxp3
+T r e g si nC O P Dp a t i e n t sa f t e rt r e a t -
ment was still significantly lower (p < 0.001) than that
in the healthy subjects (6.51 ± 1.72%) (Figure 3). These
data showed that the proportion of Foxp3
+Tregs
increased in COPD patients’ blood after SFC inhalation.
Relationship between the proportion of CD4
+CD25
+Foxp3
+ Treg cells and IL-17A levels in the serum of COPD
patients’ blood
To investigate the relationship between the levels of IL-
17A and the percentage of Foxp3
+Tregs in the serum of
Table 2 Effect of SFC therapy on lung function and
quality of life in COPD patients
Baseline SFC therapy
Pre-FEV1 (%) 39.62 ± 2.35 46.10 ± 3.58*
Pre-FEV1 (L) 1.02 ± 0.07 1.15 ± 0.13
Post-FEV1(%) 45.62 ± 2.63 49.00 ± 3.22
Post-FEV1 (L) 1.16 ± 0.08 1.27 ± 0.11
FVC (L) 3.19 ± 0.19 3.25 ± 0.22
FEV1/FVC (%) 36.76 ± 2.02 39.71 ± 2.65
Mean reversibility (%)
Mean reversibility (L)
14.05 ± 2.91
0.15 ± 0.03
8.19 ± 1.96
0.08 ± 0.02*
MMRC dyspnea scale 2.24 ± 0.10 1.33 ± 0.11***
6-min walk test (m) 329.52 ± 8.82 367.14 ± 7.99***
* p < 0.05, *** P < 0.001
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the proportion of Foxp3
+Tregs as a percentage of total
CD4
+ T cell number and the levels of IL-17A in periph-
eral blood. The results showed that, in baseline, the
levels of IL-17A (1.06 ng/ml) were correlation with the
proportion of Foxp3
+Tregs in total CD4
+ T cells (3.33%,
r=- 0 . 7 8 3 ,p<0 . 0 0 1 ,T a b l e5 ) .A f t e rS F Ct h e r a p y ,t h e
levels of IL-17A (0.95 ng/ml) were connect with the
proportion of Foxp3
+Tregs in total cells (4.14%, r =
-0.475, p = 0.030, Table 5). Interestingly, there were the
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Figure 2 Total cell number and neutrophils decreased in induced sputum of COPD patients after SFC therapy. (A) Photomicrograph of
Giemsa staining on sputum cells of COPD patients in Baseline (left) and SFC therapy (middle), or healthy controls (right). 20 μM. (B) Histogram
shows the numbers of total and the inflammatory cells, including neutrophils, monocytes, lymphocytes and eosinophils in the induced sputum
of COPD patients. p < 0.01, p < 0.001, compared with SFC therapy.
Table 3 Effect of SFC therapy on the levels of cytokines
in the induced sputum of COPD
Baseline SFC therapy
IL-17A (ng/ml) 0.40 ± 0.02 0.33 ± 0.03*
TNF-a (pg/ml) 802.71 ± 42.63 562.79 ± 29.76***
IL-8 (ng/ml) 43.09 ± 4.63 25.69 ± 3.50***
IL-10 (pg/ml) 39.09 ± 3.75 44.94 ± 4.92
* p < 0.05, *** p < 0.001
Table 4 Effect of SFC therapy on the levels of cytokines
in the blood of COPD
Baseline SFC therapy
IL-17A (ng/ml) 1.06 ± 0.06 0.95 ± 0.06*
TNF-a (pg/ml) 212.88 ± 13.10 148.97 ± 14.33**
IL-8 (ng/ml) 9.97 ± 0.43 7.53 ± 0.40***
IL-10 (pg/ml) 47.43 ± 7.71 50.59 ± 6.17
* p < 0.05, ** p < 0.01, *** p < 0.001
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levels (-0.11 ng/ml) and the variation percentage of
Foxp3
+Tregs in CD4
+ T cell (0.81%) before and after
SFC therapy (r = -0.492, p < 0.023, Figure 4). Obviously,
statistical analysis revealed an e g a t i v ec o r r e l a t i o no fI L -
17A levels with the augmentation of Foxp3
+ Tregs in
COPD patients’ peripheral blood by SFC therapy.
Discussion
TRISTAN, TORCH, and other randomized, placebo-
controlled clinical trials have proven that SFC therapy
for improves lung function and quality of life of patients
with COPD, reduces the risk of acute exacerbation of
symptoms [13,15,20,21], and decreases the rate of
decline in FEV1 values [22]. In our study and other
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Figure 3 CD4
+CD25
+Foxp3
+ Tregs increased in the peripheral blood of COPD by SFC therapy. Flow cytometry analysis of Foxp3
+Tregs in
COPD patients before and after SFC treatment. (A) Lymphocytes (R1) were identified based on their characteristic properties shown in the
forward scatter (FSC) and sideward scatter (SSC). (B) A representative gating was set for CD4
+ T cells from blood lymphocytes (R2). (C) A
representative dot plots showing expression of CD25
+Foxp3
+ Tregs in blood CD4
+ T cells of COPD before SFC therapy (Baseline). (D) In COPD
after SFC therapy, a representative dot plots showing expression of CD25
+Foxp3
+ Tregs in blood CD4
+ T cells. (E) In healthy controls, a
representative dot plots showing expression of CD25
+Foxp3
+ Tregs in blood CD4
+ T cells. (F) Comparison with the percentages of CD25
+Foxp3
+Tregs (Foxp3
+Tregs) in COPD blood before and after SFC treatment by histogram. p < 0.001, compared with that in COPD patients before SFC
therapy. p < 0.01, compared with that in healthy controls.
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George’s Respiratory Questionnaire (SGRQ) scores [23],
reduced the risk of acute exacerbation of COPD,
reduced dyspnea according to the MMRC scale, and
increased the in the 6-min walk distance. For example,
Barners et al. found that SFC significantly improved
pre-FEV1 values [16], and Celli et al. found that SFC
decreased the rate of FEV1 decrease in COPD patients
[22]. Our results and those of others indicate that long-
term SFC administration can improve clinical endpoints.
However, the mechanism underlying the effects of SFC
therapy on COPD is unclear.
COPD is defined as an “abnormal inflammatory
response” disease [24]. Therefore, development of anti-
inflammatory treatments for COPD is extremely impor-
tant. It has been suggested that SFC may have anti-
inflammatory effects on COPD. However, there is still
significant controversy regarding this subject [25]. Barnes
et al. found that SFC therapy can significantly reduce the
numbers of CD8
+ or CD4
+ T cells in the bronchial
mucosa, but has no effect on the number of CD68
+ cells
(monocytes/macrophages). More importantly, their study
was the first to show that SFC therapy reduced the num-
ber of neutrophils in induced sputum [16]. Our findings
are consistent with those of their report. Bourbeau et al.
found that the numbers of CD8
+ cells and CD68
+ macro-
phages were reduced by treatment with SFC compared to
that with a placebo, but not by treatment with FC alone.
SFC therapy did not significantly change neutrophil
numbers relative to placebo [26]. However, there were
only 9 cases of SFC therapy in the group investigated by
Bourbeau et al., which may weaken the viability of their
conclusion due to the small sample size.
Our study also confirmed that SFC therapy significantly
reduced the levels of two important inflammation mar-
kers, IL-8 and TNF-a, in induced sputum. IL-8 is a che-
motactic factor of leukocytes and lymphocytes.
Neutrophils and CD8
+ T lymphocytes are major inflam-
matory effector cells in COPD. IL-8 may activate neutro-
phils, thereby mediating the inflammatory response in
COPD [7]. Treatment with salmeterol/FC (100/1000 μg
daily) for 3 months has been reported to significantly
reduce the level of IL-8 in induced sputum [25]. Mean-
while, cigarette extracts were shown to stimulate
Table 5 Correlation analysis on the levels of IL-17A and the percentage of Foxp3
+Tregs in CD4
+ T cells in the
peripheral blood of COPD by SFC therapy
Baseline SFC therapy Alteration r1 r2 r3
IL-17A (ng/ml) 1.06 ± 0.06 0.95 ± 0.06 -0.11
Foxp3
+Tregs (%) 3.33 ± 0.23 4.14 ± 0.21 0.81 -0.783*** -0.475* -0.492*
r1 = -0.783, ***p < 0.001, levels of IL-17A vs. Foxp3
+ Tregs before SFC therapy (Baseline)
r2 = -0.475, * p < 0.05, levels of IL-17A vs. Foxp3
+Tregs after SFC therapy
r3 = -0.492, * p < 0.05, alteration of IL-17A vs. Foxp3
+Tregs in COPD by SFC therapy
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Figure 4 Relationship between the IL-17A levels and the percentage of Foxp3
+Tregs in the peripheral blood of COPD by SFC therapy.
Statistical analysis showed that there were negative correlation between the diversity of the IL-17A levels and the variation percentage of Foxp3
+Tregs in the peripheral blood of COPD after SFC therapy (r = -0.492, p < 0.05). Correlations were determined by Spearman’s rank correlation
coefficients.
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this response could be inhibited by FC in a dose-depen-
dent manner. Furthermore, the anti-inflammatory effect of
FC could be enhanced by salmeterol, suggesting that sal-
meterol and FC have synergistic anti-inflammatory effects
[27]. Similar synergistic effects of these drugs on IL-8
levels were also reported [28]. IL-8 seems to account, to
some extent, for the effects of SFC on neutrophils.
TNF-a is mainly produced by monocytes and macro-
phages after infection. TNF-a can induce monocytes/
macrophages to produce IL-8, which activates neutrophils
and stimulates them to undergo chemotaxis. Activated
neutrophils can release large amounts of reactive oxygen
species, proteolytic enzymes, lipids, and cytokines, which
further aggravate lung injury [28]. In COPD pathogenesis,
TNF-a can also stimulate epithelial cells to release mono-
cytes/macrophage- or neutrophil-derived chemotactic fac-
tors [29], leading to injury and remodeling of lung tissue.
Many studies have confirmed that the degree of TNF-a
elevation in the peripheral blood of COPD patients is clo-
sely related to the severity of COPD symptoms [30-32].
Baners et al. reported that SFC reduced the expression of
TNF-a in the bronchial mucosa of COPD patients [16]. In
addition, we found that SFC reduced the levels of TNF-a
and IL-8 in the peripheral blood of COPD patients.
We also identified a significant decrease in IL-17A levels
in induced sputum after SFC therapy. IL-17A, secreted by
Th17 cells, induces airway epithelial cells to release IL-8
and granulocyte macrophage colony-stimulating factor
(GM-CSF). GM-CSF stimulates neutrophils and macro-
phages to proliferate and undergo chemotaxis, and thus
activates the inflammatory response in COPD. IL-17A can
also induce the release of matrix metalloproteinase
(MMP)-9, which is involved in emphysema [33-35]. It was
previously found that the number of cells expressing IL-
17A in the bronchial mucosa was significantly increased in
COPD patients [36]. Our data also suggest that lower
levels of IL-17A after SFC therapy may be associated with
the reduced number of neutrophils in induced sputum.
More importantly, we also found that the proportion
of Foxp3
+Tregs as a percentage of total CD4
+ T cells in
the peripheral blood of COPD patients was significantly
smaller than that in the healthy subjects, and could be
elevated significantly by SFC therapy. Foxp3
+ Tregs are
a subpopulation of T cells that have anti-inflammatory
and immunoregulatory effects, and thereby maintain T
cell homeostasis and tolerance to self-antigens [37,38].
Correlations have been found between dysfunction of
Tregs and the pathogenesis of asthma and rheumatoid
and other autoimmune diseases [39,40]. Recently, Bur-
celo et al. found that the number of Foxp3
+Tregs in
COPD patients was significantly lower than that in smo-
k e r sw i t h o u tC O P D ,b u ts h o w e dn od i f f e r e n c er e l a t i v e
to healthy subjects, which is difficult to explain. It has
been found that the number of Foxp3
+Tregs in the per-
ipheral blood of children with asthma decreased but did
not reach a significant difference compared to that in
the control subjects. However, CD4
+CD25
+ T cells in
the lungs of these patients were significantly reduced in
number. CD4
+CD25
+ T cell numbers in peripheral
blood can be significantly increased after treatment with
inhaled corticosteroids (ICS), such as FC [41]. About
the relationship between Th 17 cells (producing IL-17A)
and Foxp3
+Tregs, natural Foxp3
+Tregs inhibited Th2
polarization and Th17-driven lung inflammation in
BALB/c mice [42,43]. Anti-IL-17 treatment had signifi-
cantly fewer Th1 cells and more Treg after lymph node
infusion in aplastic anemia [44]. CD4
+Foxp3
+ Tregs
were able to control Th17 and Th17+Th1 cells in an IL-
10-dependent manner in mice colitis [45]. CD39
+ Regu-
latory T cells suppress generation and differentiation of
Th17 cells in human malignant pleural effusion [46].
These findings are consistent with our observations in
COPD patients, suggesting that ICS treatment can
increase Foxp3
+Treg cell numbers to some extent.
Foxp3
+Tregs may also contribute to the anti-inflamma-
tory effects of ICS/long-acting beta agonist (LABA)
combination therapy. In addition, we found significant
negative correlation between the number of Foxp3
+Tregs in the peripheral blood and IL-17 levels, suggest-
ing that Foxp3
+Tregs may negatively regulate the differ-
entiation of Th17 cells and IL-17 production. On the
other hand, it was also reported that there was an
increase in Tregs in COPD patients, his regulation of
inflammation depended on the between pro- and anti-
inflammatory influences [47]. Therefore, the more evi-
dence and the connection regarding Th17 cells, IL-17
and Tregs in COPD need further study in the future.
Our study demonstrates that SFC therapy has signifi-
cant anti-inflammatory effects and improves clinical
symptoms of COPD. SFC administration reduced the
levels of inflammation markers in sputum and peripheral
blood, and reduced the number of neutrophils in induced
sputum. These effects may be related to decreased levels
of IL-8 and IL-17 in induced sputum and the recovery of
normal Foxp3
+Treg cell numbers in the peripheral blood.
The anti-inflammatory effects of SFC may contribute to
its efficacy in the treatment of COPD.
Additional material
Additional File 1: Table S1.doc. Comparison with the cell numbers in
the induced sputum of COPD patients.
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